Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts

Author:

Sturtzel C.,Grissenberger S.ORCID,Bozatzi P.,Scheuringer E.,Wenninger-Weinzierl A.,Zajec Z.,Dernovšek J.,Pascoal S.ORCID,Gehl V.ORCID,Kutsch A.,Granig A.,Rifatbegovic F.ORCID,Carre M.ORCID,Lang A.,Valtingojer I.,Moll J.,Lötsch D.,Erhart F.,Widhalm G.ORCID,Surdez D.,Delattre O.,André N.,Stampfl J.,Tomašič T.ORCID,Taschner-Mandl S.ORCID,Distel M.ORCID

Abstract

AbstractZebrafish xenotransplantation models are increasingly applied for phenotypic drug screening to identify small compounds for precision oncology. Larval zebrafish xenografts offer the opportunity to perform drug screens at high-throughput in a complex in vivo environment. However, the full potential of the larval zebrafish xenograft model has not yet been realized and several steps of the drug screening workflow still await automation to increase throughput. Here, we present a robust workflow for drug screening in zebrafish xenografts using high-content imaging. We established embedding methods for high-content imaging of xenografts in 96-well format over consecutive days. In addition, we provide strategies for automated imaging and analysis of zebrafish xenografts including automated tumor cell detection and tumor size analysis over time. We also compared commonly used injection sites and cell labeling dyes and show specific site requirements for tumor cells from different entities. We demonstrate that our setup allows us to investigate proliferation and response to small compounds in several zebrafish xenografts ranging from pediatric sarcomas and neuroblastoma to glioblastoma and leukemia. This fast and cost-efficient assay enables the quantification of anti-tumor efficacy of small compounds in large cohorts of a vertebrate model system in vivo. Our assay may aid in prioritizing compounds or compound combinations for further preclinical and clinical investigations.

Funder

Österreichische Forschungsförderungsgesellschaft

OeAD-GmbH

Österreichischen Akademie der Wissenschaften

Comprehensive Cancer Center Forschungsförderung der Initiative Krebsforschung, MedUni Wien

Vienna Science and Technology Fund

EC | Horizon 2020 Framework Programme

Javna Agencija za Raziskovalno Dejavnost RS

Sanofi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3